Moderna Inc.’s MRNA shares were down 2.8% in trading on Tuesday. Pfizer Inc. PFE, which makes a competing COVID-19 vaccine to Moderna’s Spikevax, on Tuesday put out guidance for 2023, saying it expects a total of $13.5 billion in sales of its COVID shot for the year. That’s a much lower projection than the $37.8 billion in revenue that was generated by Pfizer and BioNTech’s BNTX COVID vaccine in 2022. Moderna’s COVID vaccine is expected to bring in $18.1 billion in sales for 2022 and $7.3 billion in 2023, according to the FactSet consensus. The company is set to report its fourth-quarter results on Feb. 23. Its stock is up 3.3% over the past year, while the broader S&P 500 SPX is down 7.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.